

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: A61K 31/00	A2	(11) International Publication Number: WO 00/66104 (43) International Publication Date: 09 November 2000 (09.11.2000)
(21) International Application Number: PCT/US00/11550 (22) International Filing Date: 28 April 2000 (28.04.2000) (30) Priority Data: 60/132,034 30 April 1999 (30.04.1999) US 60/171,052 16 December 1999 (16.12.1999) US (60) Parent Application or Grant MILLENNIUM PHARMACEUTICALS, INC. [/]; (). ACTON, Susan, L. [/]; (). OCAIN, Timothy, D. [/]; (). GOULD, Alexandra, E. [/]; (). DALES, Natalie, A. [/]; (). GUAN, Bing [/]; (). BROWN, James, A. [/]; (). HANLEY, Elizabeth, A. ; ().		Published
(54) Title: ACE-2 INHIBITING COMPOUNDS AND METHODS OF USE THEREOF (54) Titre: COMPOSES INHIBANT ACE-2 ET LEURS PROCEDES D'UTILISATION (57) Abstract <p>ACE-2 inhibiting compounds are disclosed. Methods of using the compounds and pharmaceutical compositions containing the compounds are also claimed.</p> (57) Abrégé <p>L'invention concerne des composés inhibant ACE-2 ainsi que des procédés d'utilisation de compositions pharmaceutiques contenant lesdits composés.</p>		

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 31/00	A2	(11) International Publication Number: WO 00/66104 (43) International Publication Date: 9 November 2000 (09.11.00)
(21) International Application Number: PCT/US00/11550 (22) International Filing Date: 28 April 2000 (28.04.00) (30) Priority Data: 60/132,034 30 April 1999 (30.04.99) US 60/171,052 16 December 1999 (16.12.99) US (71) Applicant: MILLENNIUM PHARMACEUTICALS, INC. [US/US]; 75 Sidney Street, Cambridge, MA 02139 (US). (72) Inventors: ACTON, Susan, L.; 42 Munroe Road, Lexington, MA 02421 (US). OCAIN, Timothy, D.; 45 Indian Head Road, Framingham, MA 01701 (US). GOULD, Alexandra, E.; 23 R. Fairmont Street, Cambridge, MA 02139 (US). DALES, Natalie, A.; 26 Fisher Road, Arlington, MA 02476 (US). GUAN, Bing; 27 Shepard Street, Brighton, MA 02435 (US). BROWN, James, A.; 1099 Edgell Road, Framingham, MA 01701 (US). (74) Agents: HANLEY, Elizabeth, A.; Lahive & Cockfield, LLP, 28 State Street, Boston, MA 02109 (US) et al.		(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW. ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: ACE-2 INHIBITING COMPOUNDS AND METHODS OF USE THEREOF (57) Abstract ACE-2 inhibiting compounds are disclosed. Methods of using the compounds and pharmaceutical compositions containing the compounds are also claimed.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

ACE-2 INHIBITING COMPOUNDS AND METHODS OF USE THEREOF

Background of the Invention:

Hypertension, or high blood pressure, is the most common disease affecting the heart and blood vessels. Statistics indicate that hypertension occurs in more than 50 million Americans. The prevalence of hypertension increases with age. Between 85 and 90% of cases are primary (i.e., essential) hypertension, i.e., a persistently elevated blood pressure that cannot be attributed to any particular organic cause. The remaining percentage of cases are secondary hypertension, i.e., elevated blood pressure having an identifiable underlying cause such as kidney disease and adrenal hypersecretion.

Hypertension is of considerable concern because of the harm it can do to the heart, brain, and kidneys if it remains uncontrolled. The heart is most commonly affected by high blood pressure. When blood pressure is high, the heart uses more energy in pumping against the increased resistance caused by the elevated arterial blood pressure. Because of the increased effort, the heart muscle thickens and the heart becomes enlarged and needs more oxygen. If it cannot meet the demands put on it, angina pectoris or even myocardial infarction may develop. Hypertension can result in numerous complications including left ventricular failure; atherosclerotic heart disease; retinal hemorrhage, exudates, papilledema, and vascular accidents; cerebrovascular insufficiency with or without stroke; and renal failure. An untreated hypertensive patient is at great risk of developing disabling or fatal left ventricular failure, myocardial infarction, cerebral hemorrhage or infarction, or renal failure at an early age. Hypertension is the most important risk factor predisposing to stroke and is an important risk factor predisposing to coronary atherosclerosis.

An abnormal blood pressure can also result from specific conditions or diseases, such as heart failure. Heart failure is a chronic or acute state that results when the heart is not capable of providing sufficient cardiac output to satisfy the metabolic needs of the body. Heart failure is commonly referred to as congestive heart failure (CHF), since symptoms of increased venous pressure (pulmonary congestion with left heart failure and peripheral edema with right heart failure) are often predominant. Symptoms and signs of CHF include fatigue, peripheral and pulmonary edema, and visceral congestion (e.g., dyspnea). These symptoms are produced by diminished blood flow to the various

5 tissues of the body and by accumulation of excess blood in the various organs, that
results from the heart being incapable of pumping out the blood. Heart failure can result
10 from several underlying diseases, most commonly in industrialized nations from
atherosclerotic coronary artery disease with myocardial infarction. Myocarditis, various
5 cardiomyopathies, and valvular and congenital defects may also result in heart failure
(Anderoli et al., Cecil: Essentials of Medicine, Third Edition, WB Saunders Company,
1993). A major problem in CHF is the inability of the failing left ventricle to maintain a
15 normal blood pressure, thus resulting in increased pre- and afterload, and leading to
progressive ventricular dilation with wall remodeling. Vasodilators which induce a
10 reduction in pre- and afterload, i.e., reduction of the systemic vascular resistance and
reduction of the peripheral vascular resistance, respectively, are currently used to treat
20 CHF (Lionel H. Opie, Drugs for the Heart, Third Edition, WB Saunders Company,
1991).

25 One important system involved in regulating blood pressure is the renin-
15 angiotensin-aldosterone system. In this system, renin, a proteolytic enzyme formed in
the granules of the juxtaglomerular apparatus cells catalyzes the conversion of
angiotensinogen (a plasma protein) into angiotensin I, a decapeptide. This inactive
30 product is then cleaved by a converting enzyme, termed angiotensin converting enzyme
(ACE) mainly in the lung, but also in the kidney and brain, to an octapeptide,
20 angiotensin II, which is a potent vasoconstrictor and also stimulates the release of
aldosterone. Aldosterone is an adrenal cortex hormone that promotes the retention of
35 salt and water by the kidneys and thus increases plasma volume, resulting in an increase
in blood pressure. Angiotensin II also stimulates the release of norepinephrine from
neural cells which interacts with specific receptors on blood vessels, thereby resulting in
40 25 an increase in calcium and vasoconstriction. Another mechanism by which angiotensin II
induces vasoconstriction is by interacting with specific receptors on blood vessels,
thereby resulting in an opening of calcium channels and an increase in calcium, resulting
in vasoconstriction.

45 ACE, also referred to as peptidyl dipeptidase A (EC 3.4.15.1) and kininase II is a
30 metalloproteinase, more particularly a zinc peptidase which hydrolyses angiotensin I and
other biologically active polypeptides, such as kinins, e.g., bradykinin. Bradykinin is a
50 vasodilator, which acts at least in part by inducing release of vasodilator prostaglandins,

and which is inactivated upon hydrolysis by ACE. Thus, ACE increases blood pressure at least in part by producing angiotensin II, a vasoconstrictor, and by inactivating bradykinin, a vasodilator. Bradykinin is also involved in other biological activities including mediation of pain and inflammatory reactions.

The role of ACE in regulating blood pressure is further demonstrated at least by the efficacy of ACE inhibitors in reducing hypertension and treating CHF in individuals. ACE inhibitors have major roles as vasodilators in hypertension and CHF and are among the most efficient drugs for treating these disorders (see, e.g., Opie et al., Angiotensin Converting Enzyme Inhibitors and Conventional Vasodilators, in Lionel H. Opie, *Drugs for the Heart*, Third Edition, WB Saunders Company, 1991, p106). Several clinical trials indicate that ACE inhibitors prolong survival in a broad spectrum of patients with myocardial infarction and heart failure, ranging from those who are asymptomatic with ventricular dysfunction to those who have symptomatic heart failure but are normotensive and hemodynamically stable. For example, one study demonstrated a 40% reduction in mortality at 6 months in patients with severe heart failure (The CONSENSUS Trial Study Group, *N. Engl. J. Med.* 316:1429 (1987); The CONSENSUS Trial Study Group, *N. Engl. J. Med.* 325:293 (1991)).

Several ACE inhibitors are currently available on the market (e.g., CAPTOPRIL, ENALAPRIL, FOSINOPRIL, LINSINOPRIL, and RAMIPRIL). However, ACE inhibitors in large doses can cause a variety of undesirable secondary effects including nephrotic syndrome, membranous glomerulonephritis, nephritis, and leukopenia, as well as angioedema. Therefore, it would be advantageous to identify alternate therapies useful for treating blood pressure disorders, (e.g., hypertension) to avoid the side effects and improve the efficacy associated with the ACE inhibitors currently available.

Summary of Invention:

The invention pertains to, at least in part, compounds and methods for modulating the activity of ACE-2. In one embodiment, the invention features an ACE-2 inhibiting compound of the formula (I):

30

Z-L

(I)


wherein Z is a zinc coordinating moiety, and L is an amino-acid mimicking moiety. In one embodiment, L is an amino acid mimic containing a non-polar side chain. In an advantageous embodiment, Z is a carboxylic acid or a cleavable prodrug moiety.

In another embodiment, the invention features an ACE-2 inhibiting compound of the formula (II):

Z-A-B-E (II)

wherein Z is a zinc coordinating moiety, E is an enzyme coordinating moiety, A is an auxiliary ACE-2 pocket binding moiety, and B is an ACE-2 side chain pocket binding moiety.

In another embodiment, the invention pertains to an ACE-2 inhibiting compound of the formula (III):



(III)

wherein R^6 is hydroxyl or a protecting prodrug moiety; R^7 is a carboxylic acid, arylaminocarboxy, aroyl, alkylaminocarboxy, aminocarboxy, alkenylaminocarboxy, a protecting prodrug moiety, hydroxyl, heterocycle, alkoxy, ether, thiol or an amine; R^8 is hydrogen, or alkyl, and optionally linked to D to form a cyclic structure; R^9 is lower alkyl or hydrogen; Q is a bond, O, S, CHOH, CHSH, CHNH₂, CHNHR³, CHNR³R⁴, NH, NR³, (CH₂)_n, O(CH₂)_n, (CH₂)_nO(CH₂)_n, wherein n is either 0, 1, 2, or 3, and R³ and R⁴ are each independently substituted or unsubstituted C₁-C₅ branched or straight chain alkyl, C₂-C₅ branched or straight chain alkenyl, substituted or unsubstituted acyl, aryl, C₃-C₈ ring, optionally substituted with up to four heteroatoms; G is a linking moiety; M is an anchor moiety; J is a bond, an alkyl, alkenyl, or alkynyl moiety; D is hydrogen, alkyl, amine, hydroxy, alkenyl, alkynyl, aryl, or heteroaryl, optionally linked to G, M or Q to form a ring; t is 0, 1, 2, or 3; p is 0, 1, 2, 3, 4, or 5; q is 0, 1, 2, or 3.